Riddick Jie’s Post

A Hot-off-the-Press Publication: Landmark Review of Umbilical Cord and Wharton's Jelly Mesenchymal Stem Cell Therapies As a physician in the field of regenerative medicine, I believe this is definitely a must-read review regarding the latest advances in stem cell therapies and their applications, that covers both preclinical and clinical studies, providing a thorough analysis of the therapeutic potential of UC-MSCs and WJ-MSCs. The authors provide thorough descriptions into the mechanisms by which these stem cells and their extracellular vesicles (EVs) exert their therapeutic effects, including immunomodulation, anti-inflammatory properties, and promotion of tissue regeneration, making it a robust and up-to-date review. In addition, the immune-privileged status of UC-MSCs and WJ-MSCs with minimal ethical concerns highlights their superiority over other stem cell sources. Speaking of key aspects: In the area of bone and cartilage regeneration, UC-MSCs and WJ-MSCs enhance osteocalcin synthesis and inhibit osteoclast activity, thus showing promise in the treatment of osteoarthritis. Similarly, in liver and kidney diseases, UC-MSCs can differentiate into hepatocyte-like cells to reduce liver fibrosis, while WJ-MSCs improve kidney function by reducing renal fibrosis. Furthermore, in neurological disorders, UC-MSCs and WJ-MSCs offer neuroprotection for conditions such as Parkinson's, Alzheimer's, and spinal cord injuries by modulating neuroinflammation and promoting neuronal regeneration. In cardiovascular health, these stem cells exhibit anti-apoptotic and anti-fibrotic effects, which are beneficial in treating myocardial infarction and heart failure. This review provides clear and evidence-based understanding of UC-MSCs and WJ-MSCs, and even potential real-world clinical practices, through as-current-as-it-gets data on both published and still in-progress trials. Through research driven by innovation toward therapies that improve longevity and well-being, quality of life remains a top priority. Join us at RMI in advancing the frontier of regenerative medicine. #RegenerativeMedicine #StemCellTherapy #ClinicalResearch #HealthcareInnovation #MedicalScience #TissueEngineering

Stem Cell Placenta Implant for Degenerative Disease Victims in Mexico Stem cell placenta implant therapy is gaining recognition as a groundbreaking treatment for individuals suffering from degenerative diseases in Mexico. This innovative approach uses stem cells derived from placental tissue to regenerate damaged tissues and improve patient outcomes. Here are five key points about this therapy: 1. Regenerative Potential Placental stem cells have a unique ability to differentiate into various cell types, promoting the repair and regeneration of damaged tissues in conditions like Parkinson’s disease, multiple sclerosis, and osteoarthritis. 2. Minimally Invasive Procedure The implantation process is typically minimally invasive, often involving injections, which reduces recovery time and discomfort compared to traditional surgical methods. 3. Reduced Risk of Rejection Placental stem cells are less likely to be rejected by the patient's immune system compared to other types of stem cells, making the therapy safer and more effective. 4. Accessible Treatment Option Mexico has become a hub for advanced stem cell therapies, offering accessible and often more affordable treatment options for patients from around the world. 5. Enhanced Quality of Life Patients undergoing stem cell placenta implant therapy often experience significant improvements in their symptoms, leading to better mobility, reduced pain, and overall enhanced quality of life. As this therapy continues to evolve, it offers new hope for those afflicted by degenerative diseases. Let's be part of this journey towards innovative and life-changing treatments. #StemCellPlacentaImplant #DegenerativeDisease #Mexico #PlacidWay #MedicalTourism

Stem cell therapy: a game-changer for inflammatory bowel disease? A recent review in the World Journal of Stem Cells explores the potential of mesenchymal stem cells (MSCs) in treating IBD: https://buff.ly/3BE8gBk As a medical student focused on proactive medicine, I'm excited by the findings: • MSCs can reduce inflammation and promote mucosal healing • They've shown promise in treating Crohn's disease fistulas • Intravenous MSC infusions have improved IBD symptoms But how do these stem cells work their magic? 1. They migrate to inflamed areas 2. Secrete anti-inflammatory factors 3. Promote regulatory T cell formation 4. Support tissue regeneration It's like having a team of tiny, specialized healers targeting the root cause of IBD. The study suggests MSCs could offer hope for patients who don't respond well to current therapies. What's your take on this? Am I being overly optimistic about stem cell potential? While more research is needed to optimize protocols and assess long-term safety, the possibilities are intriguing. Imagine a future where we can effectively manage IBD without the limitations of current treatments. It's an exciting time in gastroenterology! #StemCellTherapy #IBDTreatment #MedicalInnovation

Did you know that stem cell secretome, which comprises a variety of bioactive factors like growth factors, cytokines, and exosomes, plays a crucial role in the healing process of chronic plantar ulcers in leprosy patients. The paracrine activity of stem cells, rather than direct cell replacement, is established as being the primary mechanism behind the therapeutic effects[1]. The secretome of stem cells contains essential components that aid in tissue repair, such as regulating apoptotic processes, promoting proliferation, migration, and differentiation of cells[2]. Studies have shown that the application of mesenchymal stem cell (MSC)-derived secretome can effectively expedite the healing of lepromatous ulcers as well as other types of chronic wounds such as diabetic ulcers, leading to significant improvements in wound closure and overall healing[3]. This paracrine effect of the secretome is attributed to its ability to deliver growth factors and immunomodulatory factors to target cells, activating pro-survival pathways and promoting tissue regeneration[4]. [1] F R Natallya et al., 2019. Effective Healing of Leprosy Chronic Plantar Ulcers by Application of Human Amniotic Membrane Stem Cell Secretome Gel. [2] Ping Kuen Lam et al., 2018. Topical Application of Adipose-Derived Mesenchymal Stem Cells in the Treatment of a Non-Healing Ulcer in a Leper: A Case Report - A New Option for Treatment of Extremely Chronic Ulcer [3] Medhi Denisa Alinda et al., 2022. The efficacy of topical adipose mesenchymal stem cell-conditioned medium versus framycetin gauze dressing in chronic plantar ulcer of leprosy: A randomized controlled trial. [4] Jufeng Xia et al., 2021. Researches and Applications of Stem Cell Secretome #pioneeringsecretome #woundhealing #celligenics Graphic of normal vs. diabetic wound taken from: Harold, Brem., Marjana, Tomic-Canic. (2007). Cellular and molecular basis of wound healing in diabetes. Journal of Clinical Investigation, 117(5):1219-1222. doi: 10.1172/JCI32169

## 🌟 Exploring the Potential of Stem Cell Therapy for Liver Cirrhosis and Fibrosis 🌟 Liver cirrhosis and fibrosis represent significant global health challenges, often leading to severe complications and decreased quality of life. Traditional treatment options have limitations, creating a pressing need for innovative therapeutic approaches. I am excited about the emerging role of stem cell therapy in the treatment of liver diseases. Recent studies have shown that mesenchymal stem cells (MSCs), derived from sources such as bone marrow and adipose tissue, have the potential to regenerate damaged liver tissue, reduce inflammation, and enhance liver function. Here's why this is a promising area of research: - **Regenerative Potential:** MSCs can differentiate into hepatocyte-like cells and secrete growth factors and cytokines that promote tissue repair and regeneration. - **Immunomodulatory Effects:** By modulating the immune response, MSCs may help combat the inflammatory processes that drive liver fibrosis and cirrhosis. - **Minimally Invasive Options:** Stem cell therapies can often be administered through less invasive procedures compared to traditional liver transplants, making them more accessible. While the promise of stem cell therapy for liver cirrhosis and fibrosis is evident, ongoing research is vital to fully understand its safety, efficacy, and long-term outcomes. It’s essential for clinicians and researchers to collaborate closely to explore these innovative strategies and provide evidence-based treatment options for patients. 💡 I welcome discussions with fellow professionals, researchers, and advocates in the field of liver disease. Together, we can help bring cutting-edge solutions to those affected by liver cirrhosis and fibrosis! #LiverHealth #Cirrhosis #Fibrosis #StemCellTherapy #RegenerativeMedicine #HealthcareInnovation #ClinicalResearch Feel free to adjust any part of the write-up to better fit your voice or specific audience!

ICYMI: Cornea Update: Global Consensus on the Management of Limbal Stem Cell Deficiency: Purpose: In recent decades, the medical and surgical treatment of limbal stem cell deficiency (LSCD) has evolved significantly through the incorporation of innovative pharmacological strategies, surgical techniques, bioengineering, and cell therapy. With such a wide variety of options, there is a need to establish a global consensus on the preferred approaches for the medical and surgical treatment of LSCD. Methods: An international LSCD Working Group was established by the Cornea Society in 2012 and divided into subcommittees. Four face-to-face meetings, frequent email discussions, and teleconferences were conducted since then to reach agreement on a strategic plan and methods after a comprehensive literature search. A writing group drafted the current study. Results: A consensus in the medical and surgical management of LSCD was reached by the Working Group. Optimization of the ocular surface by eyelid and conjunctival reconstruction, antiinflammatory therapy, dry eye and meibomian gland dysfunction treatment, minimization of ocular surface toxicity from medications, topical medications that promote epithelialization, and use of a scleral lens is considered essential before surgical treatment of LSCD. Depending on the laterality, cause, and stage of LSCD, surgical strategies including conjunctival epitheliectomy, amniotic membrane transplantation, transplantation of limbal stem cells using different techniques and sources (allogeneic vs. autologous vs. ex vivo–cultivated), transplantation of oral mucosal epithelium, and keratoprosthesis can be performed as treatment. A stepwise flowchart for use in treatment decision-making was established. Conclusions: This global consensus provides an up-to-date and comprehensive framework for the management of LSCD. http://dlvr.it/T9Q1Mn #Cornea #MostPopularArticles #Ophthalmology

Types of Stem Cells Based on Potency 1. Totipotent Stem Cells: These cells can give rise to all cell types, including both embryonic and extraembryonic tissues (e.g., the placenta). #Source: Zygote and the first few cells divisions in early embryos. #Therapeutic Potential: Limited direct use in therapy due to ethical concerns and difficulty in obtaining these cells. 2. Pluripotent Stem Cells (PSCs): Can differentiate into any cell type within the three germ layers: ectoderm, mesoderm, and endoderm. #Source: Embryonic stem cells (ESCs) from the inner cell mass of the blastocyst and induced pluripotent stem cells (iPSCs) reprogrammed from adult cells. #Therapeutic Potential: Broad applicability in treating a wide range of diseases, including spinal cord injuries, diabetes, and cardiovascular diseases. 3. Multipotent Stem Cells: Can differentiate into a limited range of cell types within a particular lineage or tissue. #Source: Adult stem cells such as mesenchymal stem cells (MSCs) from bone marrow, adipose tissue, and hematopoietic stem cells from bone marrow. #Therapeutic Potential: Commonly used in clinical trials and treatments for conditions like osteoarthritis, myocardial infarction, and hematological disorders. 4. Oligopotent Stem Cells: Can differentiate into a few cell types within a specific tissue or organ. #Source: Examples include myeloid or lymphoid progenitor cells. #Therapeutic Potential: Potential use in more specialized therapeutic applications related to specific tissues. 5. Unipotent Stem Cells: Can only differentiate into one cell type but retain the ability to self-renew. #Source: Examples include muscle stem cells (satellite cells) and epidermal stem cells. #Therapeutic Potential: Mainly used for tissue-specific regenerative therapies.

Mesenchymal Stem Cell Therapy (MSC) Mesenchymal stem cell therapy (MSC) is a rapidly growing field in regenerative medicine that utilizes mesenchymal stem cells, a type of multipotent stromal cell that is able to differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, and adipocytes. These cells are vital not only for their regenerative abilities, but also for their remarkable ability to modulate immune responses, making them highly effective in treating a variety of inflammatory and degenerative diseases. MSCs can be isolated from a variety of tissues, such as bone marrow, adipose tissue, umbilical cord blood, and even dental pulp. Once harvested, they can be expanded in culture and then administered to patients via local injection or intravenous infusion. This therapeutic approach is being explored for a variety of clinical applications, including bone and cartilage repair, management of chronic conditions such as heart disease and diabetes, and even for modulating immune-mediated diseases such as multiple sclerosis and graft-versus-host disease. One of the major advantages of MSC therapy is its safety, with a low risk of triggering immune rejection due to its immune-privileged nature. However, despite the potential of MSCs, challenges still remain in terms of consistency in therapeutic outcomes, understanding the exact mechanism of action, and standardizing cell preparation protocols to maximize therapeutic effects. Scientists are conducting various clinical trial studies to evaluate the therapeutic potential and limitations of MSCs, aiming to fully realize their potential in clinical applications and further establish their role in the next generation of medical treatments. References [1] Jun Zhou and Yufang Shi, Cellular & Molecular Immunology 2023 (https://lnkd.in/eVVmRUaF) [2] Na Song et al., Trends in Pharmacological Sciences 2020 (https://lnkd.in/ee2fcikE) [3] Ria Margiana et al., Stem Cell Research & Therapy 2022 (https://lnkd.in/eiqapJPv) #MesenchymalStemCells #RegenerativeMedicine #MSCTherapy #StemCellResearch #HealthcareInnovation #ChronicDiseaseManagement #Immunomodulation #ClinicalTrials #MedicalScience #FutureOfHealthcare

ICYMI: Cornea Update: Global Consensus on the Management of Limbal Stem Cell Deficiency: Purpose: In recent decades, the medical and surgical treatment of limbal stem cell deficiency (LSCD) has evolved significantly through the incorporation of innovative pharmacological strategies, surgical techniques, bioengineering, and cell therapy. With such a wide variety of options, there is a need to establish a global consensus on the preferred approaches for the medical and surgical treatment of LSCD. Methods: An international LSCD Working Group was established by the Cornea Society in 2012 and divided into subcommittees. Four face-to-face meetings, frequent email discussions, and teleconferences were conducted since then to reach agreement on a strategic plan and methods after a comprehensive literature search. A writing group drafted the current study. Results: A consensus in the medical and surgical management of LSCD was reached by the Working Group. Optimization of the ocular surface by eyelid and conjunctival reconstruction, antiinflammatory therapy, dry eye and meibomian gland dysfunction treatment, minimization of ocular surface toxicity from medications, topical medications that promote epithelialization, and use of a scleral lens is considered essential before surgical treatment of LSCD. Depending on the laterality, cause, and stage of LSCD, surgical strategies including conjunctival epitheliectomy, amniotic membrane transplantation, transplantation of limbal stem cells using different techniques and sources (allogeneic vs. autologous vs. ex vivo–cultivated), transplantation of oral mucosal epithelium, and keratoprosthesis can be performed as treatment. A stepwise flowchart for use in treatment decision-making was established. Conclusions: This global consensus provides an up-to-date and comprehensive framework for the management of LSCD. http://dlvr.it/T93jK5 #Cornea #MostPopularArticles #Ophthalmology

Therapeutic Effect of Schwann Cell-Like Cells Differentiated from Human Tonsil-Derived Mesenchymal Stem Cells on Diabetic Neuropathy in db/db Mice Yum, Y., Park, S., Nam, Y.H. et al. Tissue Eng Regen Med 21, 761–776 (2024). https://lnkd.in/gjR2vZkP Background: Diabetic neuropathy (DN) is the most common complication of diabetes, and approximately 50% of patients with this disease suffer from peripheral neuropathy. Nerve fiber loss in DN occurs due to myelin defects and is characterized by symptoms of impaired nerve function. Schwann cells (SCs) are the main support cells of the peripheral nervous system and play important roles in several pathways contributing to the pathogenesis and development of DN. We previously reported that human tonsil-derived mesenchymal stem cells differentiated into SCs (TMSC-SCs), named neuronal regeneration-promoting cells (NRPCs), which cells promoted nerve regeneration in animal models with peripheral nerve injury or hereditary peripheral neuropathy. Methods: In this study, NRPCs were injected into the thigh muscles of BKS-db/db mice, a commonly used type 2 diabetes model, and monitored for 26 weeks. Von Frey test, sensory nerve conduction study, and staining of sural nerve, hind foot pad, dorsal root ganglia (DRG) were performed after NRPCs treatment. Results: Von Frey test results showed that the NRPC treatment group (NRPC group) showed faster responses to less force than the vehicle group. Additionally, remyelination of sural nerve fibers also increased in the NRPC group. After NRPCs treatment, an improvement in response to external stimuli and pain sensation was expected through increased expression of PGP9.5 in the sole and TRPV1 in the DRG. Conclusion: The NRPCs treatment may alleviate DN through the remyelination and the recovery of sensory neurons, could provide a better life for patients suffering from complications of this disease.